Regeneron Pharmaceuticals (REGN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Antibody Therapeuticssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-28. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 2.59% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
- An $8 Billion Reason Why Regeneron Stock Is in Focus
- Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
- Sanofi pays Regeneron up to $8B to expand immunology alliance
- Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
- Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
- Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
- Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther 2026 Sep 22 PMID 42771326
- Next-generation tumor-agnostic targets on the horizon. — Trends Cancer 2026 Sep 21 PMID 42767904
- Multicentre, 2×2 factorial, randomised, open-label trial of neuromodulators and cough control therapy for refractory or unexplained chronic cough: the FORTITUDE trial protocol. — BMJ Open 2026 Sep 18 PMID 42760069
- CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer. — J Immunother Cancer 2026 Sep 18 PMID 42759982
- Acute Stroke Risk and Trends in Secondary Prevention after Retinal Artery Occlusion. — Ophthalmol Retina 2026 Sep 18 PMID 42759657
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Regeneron Pharmaceuticals.
Full REGN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.